Khooshideh Maryam, Ghaffarpour Majid, Bitarafan Sama
Department of Obstetrics and Gynecology, School of Medicine, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Neurol. 2017 Jul 6;16(3):125-129.
To date, magnesium sulphate (MgSO) is the treatment of choice for prevention of seizure in eclampsia and preeclampsia. However, there are some limitations in the administration of MgSO due to its tocolytic effects. The aim of this study was to compare the anticonvulsant and tocolytic effects of MgSO and another drug, phenytoin, in patients with eclampsia and preeclampsia. This clinical trial was conducted on pregnant women hospitalised with eclampsia or preeclampsia, during 2014-2016. The subjects were randomly assigned to two treatment groups using blocking method based on disease (eclampsia or mild and severe preeclampsia). One group received MgSO (group M) and another group received phenytoin (group P) as treatment. Each group consisted of 110 and 65 women with mild and severe preeclampsia, respectively (subgroup A), and 25 women with eclampsia (subgroup B). Duration of labor, the number of cesarean sections, convulsions and Apgar scores of infants were compared between the two groups and were considered as treatment outcomes. Convulsion rate was significantly lower with MgSO than phenytoin (P = 0.001). No seizure occurred in patients with mild preeclampsia in group P. Duration of stage one of labor (P < 0.001) and the number of cesarean sections (P = 0.040) were significantly higher in group M. However, one-minute Apgar scores for newborns were higher in women treated with MgSO compared to that of phenytoin (P = 0.001). Five-minute Apgar was not significantly different. Although MgSO is more effective than phenytoin for prevention of convulsion in eclampsia and severe preeclampsia, phenytoin may be considered for treatment of special conditions such as mild preeclampsia. Due to the tocolytic effects of MgSO on increasing the duration of labor, the increased risk of cesarean section and the potential for toxicity, physicians should critically consider the best drug according to the condition of the patient.
迄今为止,硫酸镁(MgSO)是预防子痫和先兆子痫惊厥发作的首选治疗药物。然而,由于硫酸镁具有宫缩抑制作用,其给药存在一些局限性。本研究的目的是比较硫酸镁和另一种药物苯妥英钠在子痫和先兆子痫患者中的抗惊厥和宫缩抑制作用。这项临床试验于2014年至2016年期间在因子痫或先兆子痫住院的孕妇中进行。根据疾病类型(子痫或轻度及重度先兆子痫)采用区组设计方法将受试者随机分为两个治疗组。一组接受硫酸镁治疗(M组),另一组接受苯妥英钠治疗(P组)。每组分别有110例轻度和重度先兆子痫妇女(A亚组)以及25例子痫妇女(B亚组)。比较两组之间的产程、剖宫产次数、惊厥发作情况以及婴儿的阿氏评分,并将其视为治疗结果。硫酸镁治疗组的惊厥发生率显著低于苯妥英钠治疗组(P = 0.001)。P组轻度先兆子痫患者未发生惊厥。M组第一产程时间(P < 0.001)和剖宫产次数(P = 0.040)显著更高。然而,与苯妥英钠治疗组相比,硫酸镁治疗组新生儿的1分钟阿氏评分更高(P = 0.001)。5分钟阿氏评分无显著差异。尽管在预防子痫和重度先兆子痫惊厥方面硫酸镁比苯妥英钠更有效,但对于轻度先兆子痫等特殊情况,可考虑使用苯妥英钠。由于硫酸镁的宫缩抑制作用会延长产程、增加剖宫产风险以及存在潜在毒性,医生应根据患者情况审慎考虑选择最佳药物。